Physician profile
Kara M Parker
NPI 1861855751
$9,971.44
in general payments reported to CMS, 2019-2025
45 companies · $2,923 in 2025
The $2,923 reported for 2025 was more than what 99% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,225 · 2022: $1,634 · 2023: $1,866 · 2024: $2,322 · 2025: $2,923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,111.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $1,426.19 | 2023-2025 | Gemtesa, Orgovyx |
| Abbvie INC. | $1,044.66 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $961.11 | 2021-2025 | |
| Astellas Pharma US INC | $766.29 | 2021-2025 | Xtandi, Myrbetriq |
| Endo USA, INC. | $692.05 | 2024-2025 | Xiaflex, Aveed |
| Dendreon Pharmaceuticals LLC | $578.94 | 2021-2025 | Provenge |
| Urogen Pharma, INC. | $555.37 | 2021-2025 | Jelmyto |
| Blue Earth Diagnostics | $425.37 | 2021-2024 | |
| Endo Pharmaceuticals INC. | $403.67 | 2021-2024 | Xiaflex, Aveed |
| Janssen Biotech, INC. | $368.61 | 2022-2025 | Erleada, Akeega |
| Progenics Pharmaceuticals, INC. | $301.09 | 2021-2025 | Pylarify |
| Urovant Sciences INC | $240.55 | 2021-2022 | |
| Medtronic, INC. | $228.78 | 2023-2025 | Interstim |
| Amgen INC. | $206.41 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $165.80 | 2024-2025 | Keytruda, Welireg, Lynparza |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.